Lymphoaim® (Tilmanocept) is the first and only radiopharmaceutical agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsy. Lymphoaim® provides accurate and precise lymph node identification enabling onco-surgeons make appropriate decisions in patients with breast cancer, head & neck cancer and melanomas.”